Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2021

Bispecific antibodies versus CAR T cells: Which one prevails?

Q&A

Date

21 Sep 2021

Session

Bispecific antibodies versus CAR T cells: Which one prevails?

Presenters

Pedro Romero

Authors

P. Romero

Author affiliations

  • Oncology, Ludwig Center for Cancer Research of the UNIL, 1066 - Lausanne/CH

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Introduction by the chair

Presenter: Pedro Romero

Session: Bispecific antibodies versus CAR T cells: Which one prevails?

Resources:

Slides

Webcast

Bispecific antibodies

Presenter: Roch Houot

Session: Bispecific antibodies versus CAR T cells: Which one prevails?

Resources:

Webcast

CAR T-cells

Presenter: Marcela Maus

Session: Bispecific antibodies versus CAR T cells: Which one prevails?

Resources:

Slides

Webcast

Polling 2 (led by chair)

Presenter: Pedro Romero

Session: Bispecific antibodies versus CAR T cells: Which one prevails?

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.